New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease

Area of Science:

• Oncology
• Pharmacology

Background:

• Hodgkin's disease is a cancer of the lymphatic system.
• MOPP therapy (Mechlorethamine, Oncovin, Procarbazine, Prednisone) is a standard treatment for Hodgkin's disease.
• Some patients develop resistance to MOPP therapy, necessitating alternative treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of the B-DOPA chemotherapy regimen in patients with Hodgkin's disease resistant to MOPP therapy.
• To assess response rates, duration of remission, and survival in patients treated with B-DOPA.

Main Methods:

• A prospective study involving 20 unselected patients with advanced Hodgkin's disease previously treated with MOPP therapy.
• Patients received B-DOPA chemotherapy on a specific dose schedule, with courses repeated every 3-4 weeks.
• Treatment continued until the maximum Adriamycin dose of 450 mg/m2 was reached.

Main Results:

• Fifteen of 20 patients were evaluable for response.
• A 60% complete response rate (9 patients) and a 20% partial response rate (3 patients) were observed.
• The median duration of complete remission was 14+ months, with 6 of 9 patients remaining in remission for up to 21 months.

Conclusions:

• B-DOPA is an effective combination chemotherapy regimen for advanced Hodgkin's disease in patients refractory to MOPP therapy.
• The B-DOPA regimen shows promise for integration into primary treatment protocols for advanced Hodgkin's disease.